Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Sep;22(3):309–316. doi: 10.1111/j.1365-2125.1986.tb02892.x

Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man.

T B Tjandra-Maga, R Verbesselt, A Van Hecken, A Mullie, P J De Schepper
PMCID: PMC1401142  PMID: 3094570

Abstract

The kinetics of flecainide after single intravenous (2 mg kg-1) and oral (200 mg) dosing, absolute bioavailability, effects of food and aluminium hydroxide on flecainide absorption and steady-state kinetics following twice daily oral dosing (200 mg) have been evaluated in ten healthy subjects. Absolute bioavailability of oral flecainide averaged 70% (range 60-86%). Rate and extent of flecainide absorption were not significantly affected by food nor by concomitantly administered aluminium hydroxide. The apparent volume of distribution of 5.5 +/- 0.3 l kg-1 indicates wide distribution of flecainide in tissues. Estimated elimination half-lives from plasma data averaged 9.3 to 12.4 h (single oral dose studies), 11.8 h (single i.v. dose), and 11.5 h (multiple oral dose). Half-lives calculated from urinary excretion data corresponded well with those calculated from plasma data. Flecainide elimination takes place both by nonrenal (metabolic) clearance and renal excretion of the intact drug involving glomerular filtration and active tubular secretion. Following i.v. dosing CLNR and CLR averaged respectively 3.24 +/- 0.80 and 2.38 +/- 0.49 ml min-1 kg-1. After 200 mg twice daily oral treatment steady state was reached within 3-4 days with trough and peak plasma levels on day 8 of 457 and 662 ng ml-1, which are well within the therapeutic range.

Full text

PDF
309

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson J. L., Stewart J. R., Perry B. A., Van Hamersveld D. D., Johnson T. A., Conard G. J., Chang S. F., Kvam D. C., Pitt B. Oral flecainide acetate for the treatment of ventricular arrhythmias. N Engl J Med. 1981 Aug 27;305(9):473–477. doi: 10.1056/NEJM198108273050901. [DOI] [PubMed] [Google Scholar]
  2. Chang S. F., Miller A. M., Fox J. M., Welscher T. M. Application of a bonded-phase extraction column for rapid sample preparation of flecainide from human plasma for high-performance liquid chromatographic analysis--fluorescence or ultraviolet detection. Ther Drug Monit. 1984;6(1):105–111. doi: 10.1097/00007691-198403000-00017. [DOI] [PubMed] [Google Scholar]
  3. Conard G. J., Ober R. E. Metabolism of flecainide. Am J Cardiol. 1984 Feb 27;53(5):41B–51B. doi: 10.1016/0002-9149(84)90501-0. [DOI] [PubMed] [Google Scholar]
  4. Duff H. J., Roden D. M., Maffucci R. J., Vesper B. S., Conard G. J., Higgins S. B., Oates J. A., Smith R. F., Woosley R. L. Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. Am J Cardiol. 1981 Dec;48(6):1133–1140. doi: 10.1016/0002-9149(81)90331-3. [DOI] [PubMed] [Google Scholar]
  5. Duran D., Platia E. V., Griffith L. S., Adhar G., Reid P. R. Suppression of complex ventricular arrhythmias by oral flecainide. Clin Pharmacol Ther. 1982 Nov;32(5):554–561. doi: 10.1038/clpt.1982.202. [DOI] [PubMed] [Google Scholar]
  6. Hodges M., Haugland J. M., Granrud G., Conard G. J., Asinger R. W., Mikell F. L., Krejci J. Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent. Circulation. 1982 May;65(5):879–885. doi: 10.1161/01.cir.65.5.879. [DOI] [PubMed] [Google Scholar]
  7. Johnson J. D., Carlson G. L., Fox J. M., Miller A. M., Chang S. F., Conrad G. J. Quantitation of flecainide acetate, a new antiarrhythmic agent, in biological fluids by gas chromatography with electron-capture detection. J Pharm Sci. 1984 Oct;73(10):1469–1471. doi: 10.1002/jps.2600731037. [DOI] [PubMed] [Google Scholar]
  8. Johnston A., Warrington S., Turner P. Flecainide pharmacokinetics in healthy volunteers: the influence of urinary pH. Br J Clin Pharmacol. 1985 Oct;20(4):333–338. doi: 10.1111/j.1365-2125.1985.tb05073.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. McQuinn R. L., Quarfoth G. J., Johnson J. D., Banitt E. H., Pathre S. V., Chang S. F., Ober R. E., Conard G. J. Biotransformation and elimination of 14C-flecainide acetate in humans. Drug Metab Dispos. 1984 Jul-Aug;12(4):414–420. [PubMed] [Google Scholar]
  10. Vaughan Williams E. M. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol. 1984 Apr;24(4):129–147. doi: 10.1002/j.1552-4604.1984.tb01822.x. [DOI] [PubMed] [Google Scholar]
  11. von Hattingberg H. M., Brockmeier D., Kreuter G. A rotating iterative procedure (RIP) for estimating hybrid constants in multi-compartment analysis on desk computers. Eur J Clin Pharmacol. 1977;11(5):381–388. doi: 10.1007/BF00566536. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES